State Street’s NRX Pharmaceuticals NRXP Stock Holding History

State Street’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$475K	Buy	116,084 +29,100	+33%	+$96.1K	﹤0.01%	3602
2026 Q1	$185K	Hold	86,984	–	–	﹤0.01%	3903
2025 Q4	$236K	Buy	86,984 +10,700	+14%	+$28.7K	﹤0.01%	3865
2025 Q3	$252K	Buy	76,284 +25,200	+49%	+$72.1K	﹤0.01%	3843
2025 Q2	$167K	Buy	51,084 +7,360	+17%	+$18.4K	﹤0.01%	3881
2025 Q1	$89.6K	Buy	43,724 +27,000	+161%	+$76.1K	﹤0.01%	3994
2024 Q4	$36.8K	Hold	16,724	–	–	﹤0.01%	4156
2024 Q3	$28.3K	Hold	16,724	–	–	﹤0.01%	4183
2024 Q2	$40.8K	Buy	16,724 +5,300	+46%	+$18.9K	﹤0.01%	4176
2024 Q1	$53.9K	Hold	11,424	–	–	﹤0.01%	4145
2023 Q4	$52.5K	Hold	11,424	–	–	﹤0.01%	4189
2023 Q3	$29.7K	Hold	11,424	–	–	﹤0.01%	4382
2023 Q2	$55.2K	Hold	11,424	–	–	﹤0.01%	4395
2023 Q1	$75.3K	Hold	11,424	–	–	﹤0.01%	4402
2022 Q4	$127K	Hold	11,424	–	–	﹤0.01%	4292
2022 Q3	$85K	Hold	11,424	–	–	﹤0.01%	4520
2022 Q2	$69K	Hold	11,424	–	–	﹤0.01%	4655
2022 Q1	$280K	Buy	11,424 +10,394	+1,009%	+$338K	﹤0.01%	4266
2021 Q4	$49K	Buy	+1,030	New	+$74.3K	﹤0.01%	4704

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street's NRXP Position: Q2 2026 in Review

State Street increased its NRX Pharmaceuticals (NRXP) stake by 33% in Q2 2026, buying an estimated $96.1K and bringing the position to 116,084 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #3602.

State Street first reported a position in NRXP in Q4 2021 and has held it in 19 quarters since. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

State Street held 116,084 shares of NRX Pharmaceuticals worth $475K as of Q2 2026.
State Street bought 29,100 NRX Pharmaceuticals shares in Q2 2026, an estimated $96.1K.
NRX Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3602 holding.
State Street first reported a position in NRX Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.